Search Results

Gilead’s median employee compensation in 2025 was $238,979. Daniel O’Day’s compensation package is 119 times larger.

Aprea Therapeutics, Inc. today announced that the Safety Review Committee (SRC) overseeing the ongoing ABOYA-119 clinical trial has determined that dosing of patients with ATRN-119 at 800 mg once daily (Cohort 6) can commence and that Cohort 6 is open for enrollment.

Rakuten Medical, Inc. announced the completion of a $119 million Series E preferred stock financing, including $45 million in new capital and the conversion of $74 million of convertible promissory notes with accrued interest.

Vivani Medical, Inc. announced the U.S. Food and Drug Administration has cleared the Investigational New Drug Application and lifted the clinical hold on NPM-119 to allow initiation of LIBERATE-1™, a Phase 1 clinical trial to assess the safety, tolerability and pharmacokinetics of NPM-119, the Company’s miniature, six-month GLP-1 implant in development for the treatment of type 2 diabetes.